EP 3559036 A1 20191030 - ANTI-HUMAN CXCR3 ANTIBODIES FOR TREATMENT OF VITILIGO
Title (en)
ANTI-HUMAN CXCR3 ANTIBODIES FOR TREATMENT OF VITILIGO
Title (de)
ANTI-HUMAN-CXCR3-ANTIKÖRPER ZUR BEHANDLUNG VON VITILIGO
Title (fr)
ANTICORPS ANTI-CXCR3 HUMAINS POUR LE TRAITEMENT DU VITILIGO
Publication
Application
Priority
- US 201662437889 P 20161222
- EP 17306770 A 20171214
- US 2017067988 W 20171221
Abstract (en)
[origin: CN110300763A] Provided are methods and uses of anti-CXCR3 antibodies to treat CXCR3-associated disorders such as vitiligo. In certain embodiments, the anti-CXCR3 antibodies are humanized anti-human CXCR3 antibodieswith enhanced effector function against cells expressing CXCR3 on their surface.
IPC 8 full level
C07K 16/28 (2006.01); A61P 17/00 (2006.01); A61P 37/00 (2006.01)
CPC (source: EP KR)
A61P 17/00 (2017.12 - EP KR); A61P 37/00 (2017.12 - EP KR); C07K 16/2866 (2013.01 - EP KR); A61K 2039/505 (2013.01 - EP KR); C07K 2317/14 (2013.01 - KR); C07K 2317/24 (2013.01 - EP KR); C07K 2317/41 (2013.01 - EP KR); C07K 2317/52 (2013.01 - KR); C07K 2317/56 (2013.01 - KR); C07K 2317/565 (2013.01 - KR); C07K 2317/72 (2013.01 - EP KR); C07K 2317/732 (2013.01 - EP KR); C07K 2317/734 (2013.01 - EP KR); C07K 2317/92 (2013.01 - KR); C07K 2317/94 (2013.01 - KR)
Citation (search report)
See references of WO 2018119288A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
CN 110300763 A 20191001; EP 3559036 A1 20191030; JP 2020514273 A 20200521; KR 20190095942 A 20190816
DOCDB simple family (application)
CN 201780086634 A 20171221; EP 17832143 A 20171221; JP 2019534287 A 20171221; KR 20197020838 A 20171221